Company Description
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain.
Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.
In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents.
It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023.
Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
| Country | United Kingdom |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 21 |
| CEO | Stephen Stamp |
Contact Details
Address: 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ United Kingdom | |
| Phone | 44 29 2048 0180 |
| Website | biodexapharma.com |
Stock Details
| Ticker Symbol | BDRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| CIK Code | 0001643918 |
| ISIN Number | US59564R7089 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen A. Stamp | Chief Executive Officer, Chief Financial Officer, Company Secretary and Director |
| Dr. Daniel Palmer MBA, Ph.D. | Vice President of Technology |
| Nicola Tuckwell | Vice President and Head of Clinical Operations |
| Steve Ellul | Chief Business Officer |
| Fiona Sharp | Group Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 4, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |
| Nov 12, 2024 | 424B3 | Prospectus |